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Topically Applied Hsp90 Inhibitor 17AAG Inhibits
UVR-Induced Cutaneous Squamous Cell Carcinomas
Anupama Singh1, Ashok Singh1, Jordan M. Sand1, Samuel J. Bauer1, Bilal Bin Hafeez1, Louise Meske1 and
Ajit K. Verma1
We present here that heat-shock protein 90 (Hsp90) inhibitor 17-(allylamino)-17-demethoxygeldanamycin
(17AAG), when topically applied to mouse skin, inhibits UVR–induced development of cutaneous squamous
cell carcinoma (SCC). In these experiments, DMSO:acetone (1:40 v/v) solution of 17AAG (500 nmol) was applied
topically to mouse skin in conjunction with each UVR exposure (1.8 kJ m 2). The UVR source was Kodacel-
filtered FS-40 sun lamps (approximately 60% UVB and 40% UVA). In independent experiments with three
separate mouse lines (SKH-1 hairless mice, wild-type FVB, and protein kinase C epsilon (PKCe)-over-
expressing transgenic FVB mice), 17AAG treatment increased the latency and decreased both the incidence
and multiplicity of UVR-induced SCC. Topical 17AAG alone or in conjunction with UVR treatments elicited
neither skin nor systemic toxicity. 17AAG-caused inhibition of SCC induction was accompanied by a decrease in
UVR-induced (1) hyperplasia, (2) Hsp90b-PKCe interaction, and (3) expression levels of Hsp90b, Stat3,
pStat3Ser727, pStat3Tyr705, pAktSer473, and matrix metalloproteinase (MMP). The results presented here indicate
that topical Hsp90 inhibitor 17AAG is effective in prevention of UVR-induced epidermal hyperplasia and SCC.
One may conclude from the preclinical data presented here that topical 17AAG may be useful for prevention of
UVR-induced inflammation and cutaneous SCC either developed in UVR-exposed or organ transplant
population.
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INTRODUCTION
Skin cancer is the second most commonly occurring cancer in
the United States, and about 1.3 million new cases of non-
melanoma skin cancer are diagnosed annually (Anonymous
Skin Cancer; American Cancer Society, 2014). The most
common non-melanoma forms of human skin cancer include
cutaneous squamous cell carcinoma (SCC) and basal cell
carcinoma: Goldman, 1998; Anonymous Skin Cancer;
American Cancer Society, 2014). Basal cell carcinoma is a
localized tumor and can be successfully treated surgically,
whereas SCC can metastasize to lymph nodes and lungs
(Anonymous Skin Cancer; American Cancer Society, 2014).
Chronic UVR exposure is the most common etiological factor
linked to the development of SCC. It is noteworthy that organ
transplant patients have a high incidence of SCC (Lindelo¨f
et al., 2000; Bath-Hextall et al., 2007; Ramsey et al., 2007;
Bangash and Colegio, 2012). However, the molecular
mechanisms linked to SCC formation are not well
defined. We found that protein kinase C epsilon (PKCe)
activation has an important role in UVR-induced signal
transduction pathways to the development of SCC (Wheeler
et al., 2004; Wheeler et al., 2005; Verma et al., 2006;
Sand et al., 2010). The chaperone heat-shock protein 90
(Hsp90) mediates the maturation and stabilization of PKCe
(Gould et al., 2009).
Hsp90 is a highly conserved protein and comprises about
2% of the total number of expressed cell proteins (Den and Lu,
2012; Whitesell et al., 2012; Scaltriti et al., 2012). Molecular
chaperone Hsp90 is required for the stability and maturation
of client proteins, essential for cell transformation, prolifera-
tion, and survival (Bracher and Hartl, 2006; Taipale et al.,
2012; Miyata et al., 2013). Mammalian cells contain three
types of Hsp90s: cytosolic Hsp90, mitochondrial Trap-1, and
glucose-regulated protein 94 of the endoplasmic reticulum.
Each of the Hsp90s including the bacterial homolog HtpG
hydrolyzes ATP and undergoes similar conformational
changes. Unlike the other forms of Hsp90, cytosolic Hsp90
function is dependent on a battery of co-chaperone proteins
that regulate the ATPase activity of Hsp90 or direct Hsp90 to
interact with specific client proteins (Zuehlke and Johnson,
2010). Two cytosolic Hsp90 isoforms (Hsp90a and Hsp90b)
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have been reported in humans and mice. These are
encoded by two separate genes, gene Hsp90aa1 and gene
Hsp90ab1. Cytosolic Hsp90 isoforms are highly homologous
and exhibit 85.8% sequence identity and 93.4% similarity.
Hsp90b is constitutively expressed, whereas the expression of
Hsp90a is tissue specific (Sreedhar et al., 2004). Tumor cell
oncogenic proteins require Hsp90 for their activity. Thus,
Hsp90 appears to be a potential molecular target for cancer
prevention and treatment (Stebbins et al., 1997; Neckers,
2002; So˜ti et al., 2005; Neckers, 2006; Biamonte et al., 2010).
Consequently, several Hsp90 inhibitors are being evaluated
for treatment of various human cancers (Stebbins et al.,
1997; Lindelo¨f et al., 2000; Neckers, 2002; So˜ti et al., 2005;
Neckers, 2006; Heath et al., 2008; Solit et al., 2008; Usmani
et al., 2009; Biamonte et al., 2010). However, Hsp90
inhibitors have never been investigated for prevention and
treatment of cutaneous SCC. The first Hsp90 inhibitor
used clinically was geldanamycin, which failed in clinical
trials because of liver toxicity. Second generation derivatives
such as 17-allylamino-demethoxygeldanamycin (17-AAG) do
not cause liver toxicity and are currently being evaluated in
phase II clinical trials (Heath et al., 2008; Biamonte et al.,
2010; Hubbard et al., 2011; Gartner et al., 2012; Pacey et al.,
2012).
In this communication, we evaluated the effects of
topically applied 17-AAG on UVR-induced development of
cutaneous SCC in mice. Topical applications of 17AAG in
conjunction with UVR exposures increased the latency and
decreased both the incidence and multiplicity of cutaneous
SCC. 17AAG-caused suppression of UVR-induced SCC
preceded inhibition of Hsp90b-PKCe interaction, expression
levels of Hsp90b, Stat3, pStat3Ser727, pStat3Tyr705, pAkt-
Ser473, and matrix metalloproteinase (MMP), and epidermal
hyperplasia.
RESULTS
1. PKCe is a client protein of Hsp90b
In this experiment (Figure 1), PKCe transgenic mice were
exposed once to UVR (4 kJ m2). PKCe-Hsp90b interaction
was analyzed at 1 and 2 hours post UVR treatment by co-
immunoprecipitation and western blotting. As shown in
Figure 1a, PKCe co-immunoprecipitates with Hsp90b. PKCe-
Hsp90b interaction was enhanced as early as 1 hour post UVR
treatment. To confirm the association of PKCe with Hsp90b,
we determined the co-localization of PKCe and Hsp90b by
double immunofluorescence staining. In this experiment
(Figure 1b), 5-mm thick skin sections from paraffin-fixed
samples from the indicated specimens were used. Localization
of PKCe and Hsp90b is indicated by the presence of red and
green fluorescence, respectively. The yellow fluorescence
indicates co-localization and association of PKCe with
Hsp90b. The co-localization of PKCe with Hsp90 was
observed in mouse epidermis (Figure 1bi), UVR-induced
SCC in SKH-1 hairless mice (Figure 1bii), and human SCC
(Figure 1biii). The expression of PKCe and Hsp90b was seen in
the epidermis, sebaceous gland, and the bulge region of hair
follicle. However, the expression of PKCe and Hsp90b was
lost in differentiated epidermal keratinocytes.
2. Topical 17AAG inhibited UVR-induced SCC, which was
accompanied by a decrease in: 1) hyperplasia, 2) Hsp90b-PKCe
interaction, and 3) Hsp90b, PKCe, Stat3, pStat3Ser727,
pStat3Tyr705, Akt, pAktSer473, and MMP expression levels
17AAG is an ATP antagonist and inhibits Hsp90 ATPase
activity (Stebbins et al., 1997). Inhibition of Hsp90
ATPase activity by 17AAG results in affecting the maturity
and stability of its client proteins including PKCe (Gould et al.,
2009). This led us to hypothesize that disruption of
UVR-induced interaction of Hsp90b oncogenic client
proteins by Hsp90 inhibitor 17AAG will result in the
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Figure 1. Protein kinase C epsilon (PKCe) is a client protein of heat-shock
protein 90b (Hsp90b). (a) UVR treatment increases the interaction of PKCe
with Hsp90b. PKCe-overexpressing transgenic mice (line 224; n¼3) were
exposed to UVR (4 kJ m 2) once. Mice were killed 1 or 2 hours post UVR
exposure. Epidermal protein extracts were prepared and pooled as described
before (Aziz et al., 2007). A total of 100mg of epidermal cell lysate protein was
immunoprecipitated (IP) using PKCe antibody and immunoblotted with the
Hsp90b antibody. (b) Co-localization of PKCe with Hsp90b. Co-localization of
PKCe with Hsp90b in the indicated paraffin-fixed specimen was determined by
double immunofluorescence as described (Aziz et al., 2007). The fluorescent
pictures were captured through tetramethylrhodamine channel (red color),
FITC channel (green color), and 4’,6-diamidino-2-phenylindole (DAPI; blue
color) in a Nuance (Woburn, MA, USA) fluorescent microscope (MA). DAPI/
PKCe/Hsp90b denotes the merge images of DAPI, FITC, and TRITC channel.
PKCe-overexpressing transgenic mouse skin harvested 24 hours post UVR
exposure (1.8 kJ m2) (bi), UVR-induced squamous cell carcinoma (SCC) in
SKH-1 hairless mice (bii), and human SCC (biii). Shown is the representative
picture selected from five different specimens.
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prevention of UVR-induced SCC. To test this hypothesis,
17AAG was applied topically to the skin in conjunction
with each UVR exposure. Noteworthy observations are as
follows:
I. Topically applied 17AAG is distributed both in the epidermis
and serum
In all the foregoing experiments, stock solution of 17AAG
(100 mM) was prepared in DMSO and then diluted with
acetone (DMSO:acetone: 1:40 v/v) to obtain desired dose for
topical application to the skin. As a prelude to evaluating the
biochemical and biological effects of topical 17AAG on UVR
exposed skin, we determined its distribution in the skin and
serum. In these experiments (Figure 2), 17AAG solution
(DMSO:acetone: 1:40 v/v) was applied alone or in conjunc-
tion with either acute or chronic UVR exposures. A time
course of topically applied 17AAG on epidermal and serum
levels is shown in Figure 2a. In this experiment (Figure 2),
SKH-1 hairless mice received topical 17AAG treatment
in conjunction with each three weekly UVR exposures for
25 weeks. Mice were killed for serum 17AAG analysis at 1, 3,
6, and 24 hours after last UVR exposure. Maximum serum
17AAG level was detected as early as 1 hour post topical
17AAG application (Figure 2a). In a separate acute UVR
exposure experiment with FVB mice, the level of 17AAG was
analyzed in both serum and epidermis at 6 and 24 hours post
17AAG application (Figure 2b–c). Both serum (Figure 2b) and
epidermal 17AAG (Figure 2c) levels were detectable at 6 hours
after 17AAG treatment. In both experiment with SKH-1 and
FVB mice, serum (Figure 2a and b) and epidermal 17AAG
(Figure 2c) levels reached to a minimum value at 24 hours
post 17AAG treatment. UVR treatment does not appear to
affect either the serum or the epidermal 17AAG level
(Figure 2a–c).
II. Topical 17AAG treatment suppressed Hsp90b-PKCe
interaction and expression levels of Hsp90b, Stat3, pStat3Ser727,
pStat3Tyr705, Akt, and pAktSer473
In this experiment (Figure 3), PKCe-overexpressing FVB trans-
genic mice (line 224) were exposed once to UVR. 17AAG
(500 nmol) or the vehicle was applied topically both before
and after UVR exposure. Mice were killed 24 hours post UVR
0.16
0.14
0.12
0.10
0.08
0.06
0.04
0.02
0.00
0.06 180
150
120
90
60
30
0Ep
id
er
m
al
 1
7A
AG
 (n
g/m
g)
0.05
0.04
0.03
0.02
0.01
0
6
6 (U
VR
) 24
24
 (U
VR
)
Time post topical 17AAG (hr)
17
AA
G
 in
 s
er
um
 u
g/
m
l
17
AA
G
 in
 s
er
um
 μ
g/
m
l
6
6 (U
VR
) 24
24
 (U
VR
)
Time post topical 17AAG (hr)
ND
NDNDNDNDND
SKH-1
ND
FVB FVB
1 3 6 24 I 1 3 6 24
17AAG (UVR) (hr)Vehicle (UVR) (hr)
n = 3 mice in each time point
17AAG
H2C
H3C
CH3O
H3C
CH3
OCONH2
CH3
CH3OOH
O
O
O
H
N
N
H
n = 3 mice in each time point
Figure 2. Topically applied 17-(allylamino)-17-demethoxygeldanamycin (17AAG) to the skin is distributed both in the epidermis and serum. (a) The SKH-1
hairless mice (6–7 weeks old) were exposed to UVR (1.8 kJ m 2) three times weekly (Monday, Wednesday, and Friday). The mice in the vehicle group (n¼3)
received topical treatment of 200ml vehicle (DMSO:acetone: 1:40 v/v) before and after UVR exposures. The mice in the 17AAG group (n¼3) received freshly
prepared 500 nmol of 17AAG (DMSO:acetone: 1:40 v/v) before and after each UVR exposure. All mice were treated for 25 weeks and killed at 1, 3, 6, and
24 hours post last UVR exposure. Blood samples were collected to analyze serum 17AAG by HPLC. (b, c) In a separate experiment, wild-type FVB mice (6–7
weeks old) were treated once topically with either 17AAG alone (n¼ 4) or in conjunction with a single UVR (1.8 kJ m2) exposure (n¼4). Mice of both the groups
were killed at 6 hours (n¼2) and 24 hours (n¼ 2) post 17AAG treatment. Blood samples were collected and epidermal protein lysates were prepared for 17AAG
analysis. To prepare epidermal lysate, the epidermis was scraped and homogenized in the lysis buffer. For 17AAG analysis, 50ml of epidermal lysate was used. Bar
graph illustrates the serum (a,b) and the epidermal (c) 17AAG levels. The epidermal 17AAG values were normalized with total protein concentration. Values
shown in all bar graphs are mean±SE. ND, not detectable. Inset, chemical structure of 17AAG.
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exposure. UVR exposure enhanced Hsp90b-PKCe interaction,
and 17AAG treatment in conjunction with UVR exposure
suppressed PKCe-Hsp90b interaction (Figure 3a). Also, 17AAG
treatment in conjunction with UVR inhibited Stat3, pStat3-
Ser727, pStat3Tyr705, and pAktSer473 expression levels,
but the PKCe and Akt expression levels were minimally
suppressed (Figure 3b and c). Similar results were observed
in several repeated experiments.
III. Topical 17AAG inhibited UVR-induced hyperplasia in SKH-1
mice
In this experiment, groups of SKH-1 hairless mice were
exposed four times to UVR (4 kJ m2, Monday, Wednesday,
Friday, and Monday). 17AAG (500 nmol) or the vehicle was
applied topically after each UVR exposure. The mice were
killed at 24 and 48 hours after the fourth UVR exposure. The
dorsal skin was removed and fixed in 10% formalin for the
analysis of epidermal hyperplasia. 17AAG treatment inhibited
UVR-induced hyperplasia as indicated by significant (Po0.01)
inhibition of epidermal thickness (Figure 4a and b).
IV. 17AAG-caused inhibition of UVR-induced hyperplasia in
SKH-1 mice is accompanied by a decrease in Collagen IV and
MMP, the markers of skin wrinkle formation
UVR-induced increased expression of MMP and subsequent
degradation of collagen are linked to the process of skin
wrinkle formation (Inomata et al., 2003). Also, Hsp70 has
been shown to have a role in UVR-induced wrinkle formation
(Shin et al., 2012; Matsuda et al., 2013). To obtain clues about
the anti-wrinkling property of 17AAG, we determined the
effects of topical 17AAG on UVR-induced expression levels of
MMP, collagen IV, and Hsp70 in SKH-1 mice. In this
experiment (Figure 4c and d), SKH-1 hairless mice were
exposed to UVR (2 kJ m 2) three times weekly (Monday,
Wednesday, and Friday) for 6 or 12 weeks. 17AAG (500 nmol)
or the vehicle was applied topically after each UVR exposure.
The mice were killed at 24 hours post 6- or 12-week UVR
exposures. 17AAG-caused inhibition of UVR-induced hyper-
plasia (Figure 4c) accompanied by a decrease in the protein
levels of MMP2, MMP9, and Collagen IV and a slight increase
in the protein level of Hsp70 in whole skin at 6 weeks post
UVR (Figure 4d). MMP2, MMP9, and Collagen IV are
predominantly expressed in the dermal part of the skin. To
evaluate specific change in the dermal and epidermal portions
of the skin, we separately analyzed the effect of 17AAG on the
expression levels of MMP2, MMP9, and Collagen IV in
epidermal and dermal protein lysates at 24 hours post 12-
week UVR exposures (Figure 4d). 17AAG treatment resulted in
a decrease in the protein levels of MMP2 and MMP9 in the
dermis. However, 17AAG treatment slightly increased the
level of Collagen IV in the dermis at 12 weeks post UVR.
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Figure 3. 17-(Allylamino)-17-demethoxygeldanamycin (17AAG) inhibits UVR-induced heat-shock protein 90b (Hsp90b)-protein kinase C epsilon (PKCe)
interaction and pStat3Tyr705, pStat3Ser727, Stat3, and pAktSer473 expression levels. (a) 17AAG inhibits Hsp90b-PKCe interaction. PKCe-overexpressing
transgenic mice (line 224) were exposed once to UVR (4 kJ m2). 17AAG (500 nmol) or the vehicle was applied topically both before and after UVR exposure.
Mice were killed 24 hours post-UVR exposure. There were two mice per treatment point. Dorsal skin was excised and epidermal cell lysates were prepared as
described before (Aziz et al., 2007). Pooled epidermal cell lysate was analyzed for PKCe-Hsp90b interaction by immunoprecipitation/western blot analyses. (b, c)
17AAG inhibits protein levels of Stat3, pStat3Tyr705, pStat3Ser727, and pAktSer473. PKCe-overexpressing transgenic mice (line 224) were exposed once to UVR
(2 kJ m 2). 17AAG or the vehicle was applied topically both before and after UVR exposure. Mice were killed at 24 hours post UVR exposure. There were three
mice per treatment point. Dorsal skin was excised and pooled. Epidermal cell lysates were prepared as described (Aziz et al., 2007). Pooled epidermal cell lysates
were analyzed for the expression level of the indicated proteins by the western blot analysis. (c) Shown is the quantitation of the western blot in b. Experiments
were repeated three times with similar results.
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nor in the dermis at 12 weeks post UVR (Figure 4d). 17AAG
treatment also inhibited UVR-induced proliferative marker
proliferating cell nuclear antigen (data not shown). Similar
results (Figure 4) were obtained in three separate repeat
independent experiments.
V. Topical 17AAG treatment inhibited UVR-induced
development of SCC
An initial tumor induction experiment was performed with
SKH-1 hairless mice. The Kaplan–Meier (product-limit) ‘‘sur-
vival’’ curve across time is displayed (Figure 5a). Topical
17AAG treatment increased SCC latency by 17 weeks and
significantly (P¼0.038) inhibited SCC incidence in SKH-1
hairless mice (Figure 5a). 17AAG-caused inhibition of UVR-
induced SCC (Figure 5a and b) was accompanied by inhibition
of UVR-induced hyperplasia (Figure 5c), Hsp90b, and
PKCe expression levels and an increase in the Hsp70 level
(Figure 5d). Also, topical applications of 17AAG alone did not
cause gross morphological changes in mice skin (Figure 5c).
The effects of topical 17AAG treatments on UVR-induced
development of SCC were further investigated in PKCe-over-
expressing transgenic FVB/N mice. We have previously
reported that the epidermal PKCe level dictates the suscept-
ibility of transgenic mice to the development of SCC elicited
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either by repeated exposures to UVR or by the 7,12-dimethyl-
benz[a]anthracene-12-O-tetradecanoylphorbol-13-acetate tumor
promotion protocol (Reddig et al., 2000; Jansen et al., 2001a;
Jansen et al., 2001b; Wheeler et al., 2003; Wheeler et al.,
2004; Verma et al., 2006; Aziz et al., 2007; Sand et al., 2010).
As compared with wild-type littermates, PKCe-overexpressing
transgenic mice exhibited a decrease in tumor latency and
increased in SCC multiplicity (Wheeler et al., 2004;
Sand et al., 2010). Again, topical applications of Hsp90
inhibitor 17AAG in conjunction with UVR exposures signifi-
cantly (P¼ 0.036) inhibited the development of SCC in
both PKCe-overexpressing transgenic FVB/N mice and their
wild-type littermates (P¼0.018; Figure 6).
In all of the above described tumor induction experiments
(Figure 5 and 6), 17AAG was applied before and after each
UVR exposure. We further explored the possibility that the
inhibitory effects of 17AAG on UVR-induced development of
SCC are not attributable to a sunscreen property. In this
experiment, 17AAG was applied post each UVR exposure
(Figure 6e). Topical 17AAG treatments post UVR exposures
increased SCC latency by 10 weeks and inhibited more than
50% SCC incidence (Figure 6e). However, the difference in
the SCC incidence in the vehicle and 17AAG-treated mice
was marginally significant (P¼ 0.05).
DISCUSSION
Cutaneous SCC is the second most common cancer in the
United States, with an excess of 200,000 new cases each year
(Anonymous Skin Cancer; American Cancer Society, 2014).
SCC is mainly caused by chronic UVR exposures. UVR is a
complete carcinogen, which both initiates and promotes
carcinogenesis. UVR initiates photocarcinogenesis by directly
damaging DNA (Berton et al., 1997; de Gruijl et al., 2001).
The tumor promotion component of UVR carcinogenesis,
which involves clonal expansion of the initiated cells, is
probably mediated by aberrant expression of genes altered
during tumor initiation. Specific examples are the observations
that UVR treatment results in activator protein-1 activation
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(Huang et al., 1996), upregulation of the expression levels of
p53 (Ziegler et al., 1994), ornithine decarboxylase (Rosen
et al., 1990), cyclooxygenase 2 (Isoherranem et al., 1999),
tumor necrosis factor-a, and a wide variety of cytokines and
growth factors (Enk et al., 1995), MMP, Stat3, and PKCe (Aziz
et al., 2007). Many of these molecular regulators of UVR
carcinogenesis require Hsp90 for their maturity, stability,
and activity. These several lines of independent evidence
prompted us to test the hypothesis that treatment of Hsp90
inhibitor in conjunction with UVR exposures will prevent
development of SCC. We now present that Hsp90 inhibitor
17AAG, when applied topically to the skin in conjunction
with each UVR exposure, increased the latency and decreased
both the incidence and multiplicity of UVR-induced
cutaneous SCC.
Topically applied 17AAG (500 nmol in acetone /DMSO
vehicle (DMSO:acetone: 1:40 v/v) to the skin is rapidly
distributed both in the epidermis and serum (Figure 2). As
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Figure 6. 17-(Allylamino)-17-demethoxygeldanamycin (17AAG) inhibits UVR-induced development of squamous cell carcinoma (SCC) in FVB/N protein kinase
C epsilon (PKCe)-overexpressing transgenic mice, FVB/N wild type, and SKH-1 hairless mice. (a–d) The wild-type FVB/N (n¼ 15) and PKCe-overexpressing
transgenic mice (line 224; TG; n¼ 12; 6–7 weeks old) were exposed to UVR (1.8 kJ m 2) three times weekly (Monday, Wednesday, and Friday). The mice in the
vehicle groups (WT, n¼8 and TG, n¼6) received topical treatment of 200ml vehicle (DMSO:acetone: 1:40 v/v) before and after UVR each exposure. The mice in
treatment groups (WT, n¼7 and TG, n¼6) received freshly prepared 500 nmol of 17AAG (DMSO:acetone: 1:40 v/v) before and after each UVR exposure.
Carcinomas were recorded grossly as downward-invading lesions, which were confirmed histologically. (a,c) nEvts is the number of mice at risk at the time points
listed. The log-rank statistic is computed from the expected number of deaths and actual number in each group. (b,d) Representative photographs of indicated mice
at the end of the experiment. (e) 17AAG inhibits UVR-induced SCC in SKH-1 mice even when applied post each UVR exposure. A total of 22 SKH-1 hairless mice
(6–7 week old) were divided into two groups and treated as described under Figure 5a, except 17AAG, which was applied post each UVR exposure. Line graph is
showing % of carcinoma incidence in vehicle and 17AAG-treated mice.
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both the epidermis and serum level of 17AAG declined at
24 hours post treatment, topically applied 17AAG appears to
have a short half-life (Figure 2). The pharmacokinetic of
17AAG in patients and mice has been reported (Egorin
et al., 2001; Goetz et al., 2005; Bagatell et al., 2007; Weigel
et al., 2007; Saif et al., 2013). In these reports, 17AAG was
administered intravenously or orally. 17AAG is more
bioavailable when given intraperitoneally than when given
orally. The half-life of 17AAG in these reports varied from 3 to
4 hours (Egorin et al., 2001; Goetz et al., 2005; Bagatell et al.,
2007; Weigel et al., 2007; Saif et al., 2013).
About 200 oncogenic proteins have been identified as
clients of Hsp90 (Bracher and Hartl, 2006; Taipale et al.,
2012; Miyata et al., 2013). However UVR-induced mouse
epidermal protein clients of Hsp90b remain to be identified.
Results from reciprocal co-immunoprecipitation experiments
(Figure 1 and 3) indicate interaction of PKCe with Hsp90b.
UVR treatment increases the interaction of PKCe with Hsp90b
(Figure 1). UVR exposure of mouse skin resulted in increased
expression of PKCe, possibly due to its increased synthesis
(data not shown). Newly synthesized PKC undergoes well-
ordered sequential phosphorylation for activation (Kazanietz,
2000) and Hsp90 binds newly synthesized PKCe, a required
step in its maturation and enzyme stability (Gould et al.,
2009). UVR treatment–caused increased interaction of PKCe
with Hsp90b appears to be the result of increased expression
of newly synthesized PKCe. Topical application of 17AAG to
the skin inhibited UVR-induced Hsp90b-PKCe interaction
(Figure 2). However, 17AAG did not appreciably affect the
PKCe protein level.
UVR exposure–caused skin inflammation, epidermal hyper-
plasia, and alteration in extracellular matrix (ECM) (e.g.;
damage to collagen and elastic fibers, low collagen expres-
sion, and disruption of epidermal membrane) are associated
with skin wrinkle formation (Talwar et al, 1995; Imokawa,
2009). UVR exposure has been shown to increase the
expression level of (MMPs 1, 2, 3, and 9) both in mouse
and human skin (Inomata et al., 2003; Rabe et al., 2006).
Inhibition of MMP2 and MMP9 has been shown to protect
from UVB-induced wrinkle formation and photoaging (Fisher
et al., 1996; Jung et al., 2010; Matsuda et al., 2013). In
accordance with these reports, we found that UVR exposure
induced an increased expression of MMP2 and MMP9 in the
skin of SKH-1 mice. Topical 17AAG treatment in conjunction
with UVR exposure suppressed UVR-induced increased
MMP2 and MMP9 expression level (Figure 4d). These results
indicate that 17AAG treatment may protect the skin from
UVR-caused wrinkle formation and photoaging via inhibition
of MMP2 and MMP9. Topical 17AAG treatment with each
UVR exposure effectively inhibited SCC development. As
17AAG has similar inhibitory activity when was applied
post-UVR treatment, inhibitory effects of 17AAG cannot be
attributable only to sunscreen property. The mechanism by
which topical 17AAG inhibits UVR-induced SCC is unclear.
UVR-induced development of SCC accompanies activation of
several oncogenic signal transduction pathways (Hubbard
et al., 2011). A few examples will be cited. It has been
shown that activation of mitogen-activated protein kinases
(extracellular signal–regulated kinases, p38), transcription
factors (c-fos, cjun, activator protein-11, NF-kB, Stat3, and
nuclear factor of activated T-cells), and constitutive expression
of pStat3Ser727 and pStat3Tyr705 (Aziz et al., 2007) are
linked with UVR-induced skin carcinogenesis (Huang et al.,
1996; Zhang et al., 2001; Hubbard et al., 2011; Sand et al.,
2012). UVR-activated oncogenic signal transduction pathway
(Hubbard et al., 2011) proteins are clients of Hsp90. Further
experimentation is needed to define the relative contribution
of these protein client of Hsp90 in 17AAG-caused inhibition
of UVR-induced development of SCC.
In summary, cutaneous SCC either developed in UVR
exposed or organ transplant population is a significant health
problem (Lindelo¨f et al., 2000; Bath-Hextall, et al., 2007;
Ramsay et al., 2007). Our results indicate that Hsp90 may be a
potential molecular target for the prevention of UVR-induced
development of cutaneous SCC. 17AAG can be formulated in
cream for human use for the prevention of SCC either
developed in UVR exposed or organ transplant population.
MATERIALS AND METHODS
Chemicals, antibodies, and assay kits
Antibodies to PKCe, Hsp90b, Hsp70, MMP2, MMP9, Stat3, and
b-actin were obtained from Santa Cruz Biotechnologies (Santa Cruz,
CA). Antibodies to pStat3Ser727 and pStat3Tyr705 were from BD
Biosciences (San Jose, CA). Antibodies to Akt and pAktSer473 were
purchased from Cell Signaling (Danver, MA) and to collagen IV from
abcam (Cambridge, MA). Anti-mouse, anti-goat, and anti-rabbit
secondary antibodies were purchased from Thermo Scientific (Rock-
ford, IL). 17-AAG was purchased from LC Laboratories (Woburn,
MA). 17AAG has 499% purity determined by HPLC analysis.
Kodacel filters were purchased from Unique Photo (Fairfield, NJ),
UV lamps were purchased from National Biologicals (Beachwood,
OH), and UVX-radiometer from UVP (Upland, CA).
Mice and UVR treatment
SKH-1 hairless mice were purchased from Charles River Laboratories
(Wilmington, MA). PKCe transgenic mice were generated as
described previously (Reddig et al., 2000). The UVR source was
Kodacel-filtered FS-40 sun lamps (approximately 60% UVB and 40%
UVA). Mice were exposed to UVR from a bank of six Kodacel-filtered
sunlamps. UVR dose was routinely measured using UVX-radiometer.
All of the animal protocols were approved by the University’s
Research Animal Resources Committee in accordance with the NIH
Guideline for the Care and Use of Laboratory Animals.
Western blot analysis
Mouse skin was excised and scraped to remove subcutaneous fat. The
epidermis was scraped off on an ice-cold glass plate and homo-
genized in lysis buffer (50 mmol l 1 HEPES, 150 mmol l 1 NaCl,
10% glycerol, 1% Triton X-100, 1.5 mmol l 1 MgCl2, 10mg ml
 1
aprotinin, 10mg ml 1 leupeptin, 1 mmol l 1 phenylmethylsulfonyl
fluoride , 200mmol l 1 Na3VO4, 200mmol l
 1 NaF, and 1 mmol l 1
EGTA (final pH 7.5)). The homogenate was centrifuged at 14,000g for
30 minutes at 4 1C. Epidermal cell lysate proteins were fractionated on
10% criterion precast SDS–polyacrylamide gel (Bio-Rad Laboratories,
Hercules, CA). The protein was transferred to 0.45mm Hybond-P
polyvinylidene difluoride transfer membrane (Amersham Life
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Sciences, Piscataway, NJ). The membrane was then incubated with
the indicated antibody followed by a horseradish peroxidase second-
ary antibody (Thermo Scientific), and the detection signal was
developed with Amersham’s enhanced chemiluminescence reagent
and using FOTO/Analyst Luminary Work Station (Fotodyne, WI). The
western blots were quantitated by densitometric analysis using
TotalLab Nonlinear Dynamic Image analysis software (Nonlinear
USA, Durham, NC).
Immunoprecipitation protocol
Epidermal lysates were prepared as for western blot analysis. A total
of 100mg of epidermal lysate was incubated with 10mg of the
indicated antibody. The total volume of the lysate/antibody mixture
was adjusted to 1,000ml with lysis buffer to allow for appropriate
mixing and rotated at 4 1C overnight. Lysate/antibody mixture was
then mixed with 50ml of protein agarose A/G (sc-2003 Santa Cruz
Biotechnology, Santa Cruz, CA) for 6 hours. Lysate/antibody/protein
A/G agarose mixture was then centrifuged at 8,000g for 10 minutes to
sediment the protein A/G agarose. The pellet was washed with 0.1%
tween in phosphate-buffered saline and then sedimented at 8,000g
for 10 minutes three times to wash any nonspecific binding from the
pellet. After three washes, the immunoprecipitate was boiled for
5 minutes in 20ml protein loading buffer blue (Cat # EC-886,
National Diagnostics, Atlanta, GA). Immunoprecipitates were then
treated as described above under the western Blot analysis method.
HPLC analysis of 17-AAG in serum and mice epidermis
The dorsal areas of the indicated mice (6–7 week old) were shaved
and depilated 1 day before the treatment. 17AAG stock (100 mM) was
prepared in DMSO and freshly reconstituted in acetone to a desired
concentration at the time of treatment. 17AAG or vehicle (200ml) was
applied topically to the skin either alone or in conjunction with UVR
exposures. Blood samples were collected to detect 17AAG in serum.
To prepare epidermal lysate, the epidermis was removed and
homogenized with the lysis buffer. 17-AAG levels in the serum and
mouse epidermis were analyzed by HPLC (Shin, et al., 2012).
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